Patents Examined by Zinna Northington Davis
  • Patent number: 11505552
    Abstract: A method for isolating cytisine from plant material includes dissolving the plant material in an alcohol to form a liquid mixture, acidifying the liquid mixture by addition of a mineral acid, and concentrating the liquid mixture to form a concentrated aqueous solution. The method also includes extracting the concentrated aqueous solution with a first extractant to form a purified aqueous concentrate, alkalizing the purified aqueous concentrate with an alkaloid to form an alkaline aqueous concentrate, and extracting the alkaline aqueous concentrate with a second extractant. The method further includes removing the second extractant to obtain cytisine.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: November 22, 2022
    Inventors: Danail Georgiev Metodiev, Maria Nedkova Klisarova, Petya Mitkova Apostolova, Galina Nikolova Zaekova, Nikolay Kirilov Stoyanov
  • Patent number: 11497749
    Abstract: The present disclosure relates to compounds that bind to flavin-containing enzymes and inhibit mitochondrial function, referred to herein as mitoflavoscins. Methods of screening compounds for mitochondrial inhibition and anti-cancer properties are disclosed. Also described are methods of using mitoflavoscins to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitoflavoscins to provide anti-aging benefits. Specific mitoflavoscin compounds are also disclosed.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: November 15, 2022
    Assignee: LUNELLA BIOTECH, INC.
    Inventors: Michael P. Lisanti, Federica Sotgia
  • Patent number: 11470846
    Abstract: The present invention relates to herbicidally active pyridino-/pyrimidino-thiazole derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: October 18, 2022
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Neil Brian Carter, Alison Clare Elliott, Derek McCormack, Matthew Murdoch Woodhead McLachlan, Anne Mary Seville, Matthew John Webber
  • Patent number: 11458140
    Abstract: Compounds of formula (I), wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: October 4, 2022
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Patent number: 11427539
    Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, ring A, m and n have meanings as provided in the description.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 30, 2022
    Assignee: ATROGI AB
    Inventors: Benjamin Pelcman, Tore Bengtsson
  • Patent number: 11407761
    Abstract: Provided are a novel derivative of ?-apopicropodophyllin and a method of preparing the same, and more particularly, a compound represented by Formula 1 below, which is a novel derivative of ?-apopicropodophyllin derived from podophyllotoxin, which is an anticancer agent, a method of preparing the same, and a composition for treating cancer, which includes the compound. In Formula 1, R is a C2 to C10 alkyl group, a C2 to C10 alkyl group containing an allyl- or alkyne, a —[CH2]n—C3 to C8 cycloalkyl group, a substituted or unsubstituted —[CH2]n-phenyl group, a substituted or unsubstituted —[CH2]n—C5 to C6 heteroaromatic group, a —C(?O)—C1 to C8 alkyl group, a substituted or unsubstituted —C(?O)—[CH2]n-phenyl group, or a substituted or unsubstituted —C(?O)—[CH2]n—C5 to C6 heteroaromatic group, wherein n is an integer of 0 to 6.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 9, 2022
    Assignee: J&C SCIENCES
    Inventors: Jong-Ryoo Choi, In-Young Choi, So-Yeon Nam, Se Hee Hyun
  • Patent number: 11401246
    Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: August 2, 2022
    Assignee: CANTERO THERAPEUTICS, INC.
    Inventors: Hans Maag, Miguel Xavier Fernandes, Robert Zamboni, Elham Akbariromani, Marc-Andre Beaulieu, Yves Leblanc, Pallavi Thakur
  • Patent number: 11384080
    Abstract: The invention concerns a method for isolation of cytisine from plant material. The method according to the invention, consists in extraction of the plant raw material by lower alcohol, acidified with mineral acid to pH within a range 1.5-3.5. The combined alcohol-aqueous extracts are concentrated under vacuum distillation till the alcohol is eliminated and after filtration they are extracted with chloroform, methylene chloride, butyl acetate or normal butanol in a ratio of 1:1. The purified from ballast substances acid aqueous concentrate is alkalized to pH 9-12 with alkaline hydroxide or ammonium hydroxide and the resulting alkaline aqueous concentrate is extracted at least twice with chloroform, methylene chloride, butyl acetate or normal butanol in a ratio of concentrate:extractant of 1:5 to 1:10. The combined organic extracts are evaporated to dryness, then acetone or ethyl acetate are added to obtain a suspension which is allowed to crystallize completely at 5-10° C., then it is filtered and dried.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: July 12, 2022
    Inventors: Danail Georgiev Metodiev, Maria Nedkova Klisarova, Petya Mitkova Apostolova, Galina Nikolova Zaekova, Nikolay Kirilov Stoyanov
  • Patent number: 11370799
    Abstract: The present invention relates to novel methods for the preparation of 1,3-benzo-dioxole heterocyclic compounds and intermediates for the same. The compounds are useful as PDE4 inhibitors.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 28, 2022
    Assignee: Union therapeutics A/S
    Inventors: Allan Carsten Dahl, Gitte Holm Jensen, Tine Marianne Duus
  • Patent number: 11369593
    Abstract: The present invention includes compositions and methods for treating a subject afflicted with a neurodegenerative disorder or disease by determining that the subject is in need of treatment for the neurodegenerative disorder or disease; and administering to the subject an amount of an effective amount of a compound comprising a flupirtine derivative as disclosed herein.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 28, 2022
    Assignee: Texas Tech University System
    Inventors: Paul Trippier, Nihar Kinarivala, Rose-Mary Boustany
  • Patent number: 11357757
    Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: June 14, 2022
    Assignee: ATROGI AB
    Inventor: Benjamin Pelcman
  • Patent number: 11311560
    Abstract: Provided herein are cyclic plasmenylethanolamines and plasmalogen precursors of formula A, wherein R1 and R2 are each, independently, a saturated, unsaturated, or polyunsaturated hydrocarbon group. Methods and uses thereof in the treatment of plasmalogen deficiency are also described. Cyclic plasmenylethanolamines described herein may act as plasmalogen precursors which, following administration, may be converted to at least one plasmalogen species, thereby elevating the plasmalogen level in a subject.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: April 26, 2022
    Assignee: Med-Life Discoveries LP
    Inventor: Tara Smith
  • Patent number: 11312686
    Abstract: Disclosed herein are compounds, 3,4,6,8-substituted-2-([1?-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: June 22, 2019
    Date of Patent: April 26, 2022
    Assignees: Ohio State Innovation Foundation, Hendrix College
    Inventors: John C. Byrd, Thomas E. Goodwin, Ola Elgamal, Erin Hertlein, Mouad Abdulrahim, Chad E. Bennett, Sandip Madhukar Vibhute
  • Patent number: 11292766
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: April 5, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
  • Patent number: 11229637
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: January 25, 2022
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Patent number: 11229629
    Abstract: Pharmaceutical compositions that include inhibitors of mitochondrial fission are described for the treatment and/or mitigation of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, neurological disorder, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, or alcohol-related liver disease.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 25, 2022
    Assignee: Queen's University at Kingston
    Inventors: Danchen Wu, Michael Wells, Stephen Archer
  • Patent number: 11225466
    Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: January 18, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Patent number: 11220508
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: January 11, 2022
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Silvana Marcel Leit De Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Patent number: 11219618
    Abstract: The invention provides novel pyridylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, autoimmune diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and X are as defined in the specification.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 11, 2022
    Assignee: Sprint Bioscience AB
    Inventors: Johan Lindström, Rickard Forsblom, Tobias Ginman, Fredrik Rahm, Jenny Viklund
  • Patent number: 11207408
    Abstract: The present document describes methods of using compositions for inhibiting biofilm formation, or disrupting existing or developing biofilms in a subject, which composition comprises at least one chromophore and a pharmacologically acceptable carrier.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 28, 2021
    Assignee: KLOX TECHNOLOGIES INC.
    Inventors: Remigio Piergallini, Nikolaos Loupis, David Ohayon, Kevin Wilkinson, Giovanni Scapagnini